Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Sanofi Signs MOU for Rare Disease Collaboration with Sinopharm

publication date: Oct 1, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sanofi and Sinopharm (China State Institute of Pharmaceutical Industry) signed a MOU in Shanghai to conduct joint research into rare diseases. Although details haven’t been released, the collaboration will apparently survey the incidence of rare diseases in China, then seek to understand causes and find treatments. In 2011, Sanofi paid $20 billion to acquire US-based Genzyme, a specialist in rare diseases. More details....

Stock Symbol: (NYSE: SNY)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...